LEVEL JUMP
HEALTHCARE CORP.

INTERIM MANAGEMENT DISCUSSION AND ANALYSIS

FOR THE THREE MONTHS AND SIX MONTHS ENDED JUNE 30, 2022.

(EXPRESSED IN CANADIAN DOLLARS)

FORWARD LOOKING STATEMENTS

This MD&A contains certain statements that may constitute "forward-looking statements". Forward-looking statements include but are not limited to, statements regarding future anticipated business developments and the timing thereof, regulatory compliance, sufficiency of working capital, and business and financing plans. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made, and they involve several material risks and uncertainties. Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. Forward-looking statements are typically identified by words such as: believe, expect, anticipate, intend, estimate, postulate, and similar expressions, or which by their nature refer to future events. The Company cautions investors that any forward-looking statements by the Company are not guarantees of future performance, and that actual results may differ materially from those in forward looking statements as a result of various factors, including, but not limited to, the Company's ability to continue its projected growth, to raise the necessary capital or to be fully able to implement its business strategies.

The Company has based the forward-looking statements largely on the Company's current expectations, estimates, assumptions, and projections about future events and financial and other trends that the Company believes, as of the date of such statements, may affect its business, financial condition, and results of operations. Such expectations, estimates, assumptions, and projections, many of which are beyond the Company's control, include, but are not limited to: management's expectations regarding the future business, objectives and, operations of the Company; the Company's anticipated cash needs and the need for additional financing; the Company's ability to successfully complete future financings; the acceptance by the marketplace of new technologies and solutions; the Company's expectations regarding its competitive position; the Company's expectations regarding regulatory developments and the impact of the regulatory environment in which the Company operates; the Company's ability to attract and retain qualified management personnel and key employees; and anticipated trends and challenges in the Company's business and the markets in which it operates. Assumptions underlying the Company's working capital requirements are based on management's experience with other public companies.

Forward-looking statements regarding treatment by governmental authorities assumes no material change in regulations, policies, or the application of the same by such authorities. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statements were made, and readers are advised to consider such forward-looking statements with the risks set forth.

The following Management's Discussion and Analysis ("MD&A") of Leveljump should be read in conjunction with the Company's Unaudited Consolidated Financial Statements for the period ended June 30, 2022, together with notes thereto (the "Financial Statements"). The Company's Unaudited Consolidated Financial Statements for the period ended June 30, 2022, have been prepared in accordance with International Financial Reporting Standards ("IFRS"), as issued by the International Accounting Standards Board ("IASB") and interpretations issued by the IFRS Interpretations Committee ("IFRIC"). All amounts herein are presented in Canadian dollars, unless otherwise noted. This Management's Discussion and Analysis is dated August 18, 2022 and has been approved by the Board of Directors of the Company.

The Company's Audited Consolidated Financial Statements and its Annual Information Form are available on SEDAR at www.sedar.com

OVERALL PERFORMANCE

Summary of Business

Leveljump Healthcare Corp. was incorporated under the Canada Business Corporations Act on March 21, 2019 (“Jump” or the “Company”). The Company’s registered head office is 304-85 Scarsdale Rd., Toronto, ON, Canada M3B 2R2. The Company’s website is www.leveljumphealthcare.com.

The Company’s principal business activity is providing radiology services both by providing direct patient images and by providing Teleradiology services. Teleradiology is the process of providing remote off site reading of radiology scans such as CT, MRI, US, and X-ray. Hospital staff scan their emergency room patients, then page the Company’s radiologist on call, who can then remotely view, via secured server, the images and diagnose the patient and provide a report back to the hospital.

Results for Q2 2022

Total revenue for the second quarter was very strong at $2,335,793.72 and was a nearly 42% year over year growth from the second quarter of 2021. Second quarter 2022 was also an 18% increase in revenues as compared to the first quarter of 2022.

Teleradiology revenues were $1,936,627 which was an increase of 18% compared to the second quarter of 2021. The demand for CTS services is strong. Hospitals are trying to open access to more imaging overnight for their ER departments, which would increase the patient scan volume that CTS reads.

Revenues from the IHF’s totalled $421,326 in the quarter. As we emerge from COVID, demand for imaging services is very high and as such, we have increased our hours of operations for both ultrasound and mammography, which in turn should lead to increased revenue. The Company believes this trend will continue. Additionally, CTS is preparing its marketing efforts to further increase revenue in its local communities.

During the quarter, the Company completed its PACS software migration. This new system will contribute cost savings and help us to offer one complete solution for client hospitals, along with an easy workflow and worklist reading for our radiologists.

The Company did experience a tight labour pool, as is the experience with the broader healthcare market in Ontario. Efforts continue to recruit additional radiologists to ensure fluidity in coverage.

CTS has hired a director of operations, a key role to help manage the growing business. In this role, the new director can handle overseeing the daily operations, employees, client hospitals and work on marketing efforts.

Industry Events and Trends

During the first couple of months of the quarter, COVID-19 continued to have an impact on daily life in Ontario and there were continued restrictions and backlogs, as well as a reduction in healthcare services including elective procedures. Industry focus continues to be on the emergence and benefits of telehealth operations (providing health care remotely).

As the Company was providing services to our hospital clients in this manner long before the Covid-19 pandemic this is an ideal environment for our telehealth operations.

The Company believes that there is now a greater acceptance amongst the general population for telehealth services, than existed prior to the COVID-19 outbreak, and that ultimately this will enhance and improve our ability to acquire new contracts with hospitals. Key hospital decision makers such as department heads, radiologists, and hospital CEOs are now seeing the benefits of ensuring an uninterrupted flow of patient care via telehealth.

Management believes that hospitals and the healthcare industry in general will be looking for further ways to capitalize on the benefits of remote healthcare. This trend is expected to continue at a fast pace. Healthcare companies that can capitalize on it will be best served.

The healthcare system is now working through a backlog of imaging scans that were delayed due to the pandemic. This will continue for the foreseeable future as the healthcare system as to deal with both delayed imaging waitlists and new patients that require scans. For our IHF's, we are seeing high volume of bookings for imaging scans as people return to taking care of their health.

Hospital procedures and regular doctor visits should increase due to the back log in the healthcare system from the past 12 months. We believe this may positively affect the Company as more medical imaging scans will be demanded

Outlook for 2022

Management believes that the Company's outlook for 2022 is strong based on several factors, including but not limited to, the increased demand for remote healthcare and the general population's attitude shift to accepting the idea of telehealth services. With the Q1 2022 acquisition of our IHF clinics as well as potential organic growth form current operations, the Company expects to achieve increased revenues again in the remainder of 2022.

After closing the acquisitions of the 3 IHF clinics, the Company still has some cash on hand and has been making regular payments on its long-term debt financing arrangement with TD Canada Trust. With strong demand for Company services and increasing margins, the Company is hopeful that this relationship can be expanded in the future for additional acquisitions.

The Company's focus for the remainder of 2022 will be to continue growing revenues via increased patient visits, increasing gross margins through cost reductions as well as identifying and closing further acquisitions. Management continues to identify and target acquisitions that provide both stable revenues and positive EBITDA.

The Company will also devote some time to its Leveljump Technologies subsidiary towards finding suitable products and services that fit within the Company business plans and that will impact the provision of healthcare in the future. The company currently owns an interest in Shaw Lens, which has a US patent for its eye-glass technology.

Financing and Share Issuances (See Notes 5, 11,12,13,15 in Financial Statements)

During the quarter ended June 30, 2022, the Company issued 5,846,668 units consisting of 1 common share and 1 common share purchase warrant with an exercise price of $0.20 and an expiry of March 31, 2024, for gross cash proceeds of $877,000.

On February 1, 2022, the Company's subsidiary CTS borrowed $3,200,000 from TD Canada Trust. The initial term of the loan is 5 years with an initial 2-year interest rate of 4.02%. The loan is amortized over 10 years. Payments of principal and interest on the loan are due monthly. There is an additional annual payment of principal on the balance of the loan based on 25% of EBITDA of the Company's CTS subsidiary. As of the date of this report the principal balance on the Term Loan is $3,068,421.

The Company also secured a $150,000 operating line of credit from TD Canada Trust.

LIQUIDITY AND CAPITAL RESOURCES

As at June 30, 2022, the Company had cash and cash equivalents in the amount of $1,296,558 (December 31, 2021 - $756,260). On June 30, 2022, the Company had working capital of $1,188,542 (December 31, 2021 - $721,583).

The Company's current assets as of June 30, 2022, excluding cash and cash equivalents were $2,422,572 (December 31, 2021: $1,863,970) which consisted of accounts receivable in the amount of $801,008 (December 31, 2021: $727,983), loans receivable in the amount of $1,270,251 (December 2021: $556,521), HST receivable for $167,985 (December 2021: $151,495) and prepaid expenses and deposits totalling $183,327 (December 31, 2021: $427,971).

Current liabilities as at June 30, 2022, were $2,530,588 (December 31, 2021: $1,898,377) which were comprised of accounts payables and accrued liabilities of $2,018,5578 (December 31, 2021: $1,871,797), operating line of credit $148,353 (December 2021: nil), current portion of lease liabilities $99,726 (December 31, 2021: $26,580), and current portion of long term debt $263,952 (December 31, 2021: nil).

The continuing operations of the Company are dependent upon its ability to raise adequate financing and to continue its operations in the future. For the quarter ended June 30, 2022, the Company had a net loss and comprehensive loss of $182,379 and as at June 30, 2022, an accumulated deficit of $15,175,612. These uncertainties may cast significant doubt upon the Company's ability to continue as a going concern.

Although the Company has been successful in borrowing funds or raising equity capital in the past, there can be no assurance that the Company will have sufficient financing to meet its future capital requirements, or that additional financing will be available on terms acceptable to the Company in the future. The Company has and may continue to have capital requirements in excess of its currently available resources.

Covid-19

In March 2020, the World Health Organization declared a global pandemic related to the virus known as COVID-19. The expected impacts on global commerce are anticipated to be far reaching. To date there have been significant wide-spread stock market declines and the movement of people and goods has become restricted. As the Company has no material operating income or cash flows, it will be reliant on additional financing to fund ongoing operations and future acquisitions. An extended disruption may affect the Company's ability to obtain additional financing. The impact on the economy and the Company is not yet determinable; however, the Company's financial position, results of operations and cash flows in the current period have been impacted as patient volume has decreased resulting in decreased revenues for the Company. The Company's financial position, results of operations and cash flows in future periods may be materially affected. In particular, there may be heightened risk of liquidity or going concern uncertainty.

Liquidity Risk

Liquidity risk is the risk that the Company cannot meet a demand for cash or fund its obligations as they become due. The Company's approach to managing liquidity risk is to ensure that it will have sufficient liquidity to meet liabilities as they become due. The Company is expanding and to meet its short and longer-term working capital requirements, the Company will attempt, if necessary, to secure further financing to ensure that those obligations are properly discharged. Operationally, the Company manages its liquidity by continuously monitoring forecasted and actual gross profit, expenses, and cash flows from operations. There have been no changes to this risk exposure from 2020.

The following tables illustrate the contractual maturities of financial liabilities for June 30, 2022 and December 31, 2021:

June 30, 2022	**Payments Due by Period $**				
	Total	Less than 1 year	1 – 3 years	4-5 Years	After 5 years
Accounts payable and accrued liabilities	2,018,557	2,018,557	-	-	-
Lease liabilities	330,129	99,726	191,525	38,878	
Long term debt	3,112,016	263,952	527,904	527,904	1,792,256
TOTAL	5,460,702	2,382,235	719,429	566,782	1,792,256

December 31, 2021	**Payments Due by Period $**				
	Total	Less than 1 year	1 – 3 years	4-5 Years	After 5 years
Accounts payable and accrued liabilities	1,860,373	1,860,373	-	-	-
Lease liabilities	26,580	26,580	-	-	-
Long term debt	-	-	-	-	-
TOTAL	1,886,953	1,866,953	-	-	-

CAPITAL RESOURCES

The Company defines capital as total shareholders' equity and long-term debt. The Company manages its capital structure, based on the funds available to the Company, to support the growth and development of its operations and bring new products to market and to ensure it continues as a going concern. The Board of Directors does not establish quantitative return on capital criteria for management, but rather relies on the expertise of the Company's management to sustain future development of the business. The Company will continue to assess new opportunities and seek to acquire an interest in growth situations if it feels there is sufficient economic potential and if it has adequate financial resources to do so.

Management reviews its capital management approach on an ongoing basis and believes that this approach, given the relative size of the Company, is reasonable. There were no changes in the Company's approach to capital management during the quarter ended June 30, 2022 or the year ended December 31, 2021. The Company is not subject to externally imposed capital requirements other than those on its TD Long Term Debt which include priority rights against CTS, Debt to EBITDA ratios of 2.8 times for June 30, 2022 and 2.5 times for December 31, 2022.

OFF-BALANCE SHEET ARRANGEMENTS

The Company does not have any Off-Balance Sheet arrangements.

RELATED PARTY TRANSACTIONS AND BALANCES

Related parties include key management being the Company's executive officers, the Board of Directors, close family members and enterprises that are controlled by these individuals as well as certain persons performing similar functions. The following related party transactions were conducted in the normal course of operations and were made on an arm's length basis:

Period Ended December 31,	June 30, 2022	December 31, 2021
Key management compensation	$268,638	$ 1,112,433
Share-based compensation	36,833	642,268
	$ 305,471	**$ 1,082,875**

SECOND QUARTER RESULTS

Quarter Ended	June 30, 2022	June 30, 2021
Total revenue	$2,335,794	$1,639,913
Gross margin	664,745	331,891
Operating Expenses	793,822	928,125
Net (loss) / income	(182,379)	(569,128)
Loss per share–basic and diluted	$(0.00)	$(0.01)

REVENUES

Teleradiology

For the three months ended June 30, 2022, the Company's teleradiology revenue increased by $253,955 to $1,864,794 compared to $1,610,839 for the same period in 2021.

Diagnostic Imaging Services

For the three months ended June 30, 2022, the Company's Diagnostic Imaging Services revenue was $421,326. There is no comparable data for the same period last year as this revenue was directly related to the IHF acquisition in February 2022.

Admin and Other

For the three months June 30, 2022, the Company's admin and other revenue was $49,674 which increased by $20,600 compared to admin revenue for the same period in 2020 of $29,074.

TOTAL REVENUE

Total revenue for the three months June 30, 2022, was up $695,881 to $2,335,794 compared to $1,639,913 for the three months ended June 30, 2021. The increase in total revenue is primarily a result of the revenues generated from the diagnostic imaging services.

COST OF SALES

Physician Fees

For the three months ended June 30, 2022, the Company's physician fees totaled $1,458,193 higher by $192,515 compared to physician fees of $1,265,678 for the three months ended June 30, 2021. The increase in reading fees in the current three-month period is a result of the increased operations due to increased demand for the Company's services.

Technician Fees

For the three months ended June 30, 2022, the Company's technician fees totaled $136,401. There is no comparable data for the same period last year as this was directly related to the IHF acquisition in February 2022.

Medical Imaging Software

PACS costs for the three months ended June 30, 2022, was $68,527 compared to $42,344 for the three-month period ended June 30, 2020. This increase was related to an increase in patient volume requiring diagnostic interpretation during the second quarter for 2022. Additionally, the increased costs are partially offset by amounts we are able to collect in administrative revenues.

Supplies

For the three months ended June 30, 2022, the Company's supplies costs totaled $7,928. There is no comparable data for the same period last year as this was directly related to the IHF acquisition in February 2022.

TOTAL COST OF SALES

Total cost of sales during the second quarter in 2022 including physician fees, technical fees, medical imaging software, and supplies totalled $1.671.049 compared to $1,308,022. Higher cost of sales experienced during the second quarter in 2022, was primarily a result of costs associated with the IHF acquisition in addition to increased operations due to higher demand for the Company's services.

GROSS PROFIT

As a result of the above revenues net of cost of sales, the Company's gross margin increased by $332,854 to $664,745 for the three-month period ending June 30, 2022, versus gross margin of $331,891 for the same three-month period in 2021.

EXPENSES

Stock Based Compensation

For the three months ended June 30, 2022, the Company recorded stock-based compensation of $36,833 compared to $210,263 for the same period in 2021. The decrease of $173,430 is due to a number of options vesting in the first quarter of 2022 and not repeating in the second quarter.

Salaries and Wages

For the three months ended June 30, 2022, the Company recorded salaries and wages of $208,709 compared to $323,223 for the same three-month period ended June 30, 2021. The decrease in salaries recorded in the second quarter of fiscal 2022 was a result of the re-capture of an allowance for additional payroll taxes.

Advertising and Marketing

For the three months ended June 30, 2022, the Company recorded advertising and marketing expenses for $(6,887). Marketing and advertising expenses for the same period in 2021 was $204,828. The negative balance for Marketing expenses was directly related to a reversal of an erroneous vendor invoice. The significant decrease in advertising and marketing expenses occurred in the quarter were partly for contracts signed in 2020 for investor outreach and institutional outreach related to the Company's qualifying transaction and listing on the TSXV exchange that were not continued into 2022.

Professional Fees

For the three months ended June 30, 2022, the Company recorded professional fees of $393,396 up considerably by $264,779 compared to $128,617 for the three months ended June 30, 2021. The increase in professional fees for the three months ended June 30, 2022, was primarily attributed to increased consulting fees in the second quarter due to revisions in management compensation contracts.

General and Administrative

General and administrative costs totaled $73,533 up $44,492 for the three months ended June 30, 2022, compared to general and administrative costs of $29,041 for the same three-month period in 2021. The Company experienced an increase in general and administrative costs during the current period in fiscal 2022, because of additional expenses incurred by the IHF centres.

Insurance

Insurance expense for the three months ended June 30, 2022, increased by $2,618 to $23,778 when compared to $21,160 for the same period in 2021.

Depreciation and Amortization

For the three months ended June 30, 2022, depreciation and amortization costs increased significantly by $44,856 to $53,036 compared to $8,183 for the same period in 2021. This increase was due to additional amortization and depreciation on equipment and property related to the IHF centres.

Premises Rental

For the three months ended June 30, 2022, the Company's premises rental costs increased by $8,613 to $11,424 compared to $2,811 for the same period in 2021. This increase reflects the rent due on the IHF centres.

TOTAL OPERATING EXPENSES

Total expenses for the three months ended June 30, 2022, were $793,822, lower by $134,304 when compared to total expenses of $928,126 for the three months ended June 30, 2021. The primary factors relating to the decrease in total expenses during the second quarter of 2022 were due the decrease in salaries and wages by $114,514, the stock-based compensation expenses which decrease by $173,430, and advertising and marketing expense which decreased by $211,715.

OTHER INCOME

For the three months ended June 30, 2022, other income was $1,848, whereas in 2021 for the same period it was nil. The other income is related to interest income and miscellaneous income.

OTHER EXPENSES

Finance Costs

For the three months ended June 30, 2022, the Company recorded finance costs of $36,219 which increased significantly by $33,305 versus finance costs of $2,914 for the three-month period ended June 30, 2021. The increase in finance costs during the first quarter of 2022 was primarily related to interest on the TD Loan.

Broker Commissions

For the three months ended June 30, 2022, the Company recorded broker commission costs of $20,201. There was no comparable amount for the same period in 2021 as this relates to broker commission costs from private placement financing.

Reconciliation Discrepancies

For the three months ended June 30, 2022, the Company reconciliation discrepancies of $(1,270). There was no comparable amount for the same period in 2021. These costs were directly related to reconciliation discrepancies which the company faced as a direct result of migrating between two accounting systems.

Other Miscellaneous Expenses

For the three months ended June 30, 2022 the Company did not record any miscellaneous expenses, compared to $(13,971) that was recorded for the same period in 2021. The miscellaneous expenses recorded in 2021 were related to an accounts payable write-off that were no longer due.

Foreign Exchange Loss

No foreign exchange loss was recorded in the second quarter of 2022. In the second quarter of 2021 foreign exchange loss was recorded for $3,951.

TOTAL EXPENSES

Total expenses for the three months ended June 30, 2022, were $848,972, lower by $72,048 compared to $921,020 for the three-month period ended June 30, 2021. The decrease in total expenses for the three-month period ended June 30, 2022, was primarily related to salaries and wages, stock-based compensation and advertising and marketing expenses.

NET LOSS AND COMPREHENSIVE LOSS

As a result of the above factors, the net loss and comprehensive loss for the three months ended June 30, 2022, was $182,379 compared to a net income and comprehensive loss of $589,129 for the three months ended June 30, 2021, an increase of $406,750.

LOSS PER SHARE – BASIC AND DILUTED

The loss per share-basic and diluted for the three months ended June 30, 2022 was $nil versus the income per share-basic and diluted of $(0.01) for the comparable three-month period in 2021.

SIX MONTH RESULTS

Period Ended	**June 30, 2022**	**June 30, 2021**
Total revenue	$4,321,209	$3,185,094
Gross margin	1,153,243	628,860
Operating Expenses	1,685,988	1,938,627
Net (loss) / income	(525,645)	(1,285,934)
Loss per share–basic and diluted	$(0.01)	$(0.03)

REVENUES

Teleradiology

For the 6 months ended June 30, 2022, the Company's teleradiology revenue increased by $426,092 to $3,557,863 compared to $3,131,771 in 2021.

Diagnostic Imaging Services

For the six months ended June 30, 2022, the Company's Diagnostic Imaging Services revenue was $677,371. There is no comparable data for the same period last year as this revenue was directly related to the IHF acquisition in February 2022.

Admin and Other

For the six months June 30, 2022, the Company's admin and other revenue was $85,971 which increased by $32,650 compared to admin revenue for the same period in 2021 of $53,324.

TOTAL REVENUE

Total revenue for the six months June 30, 202, was up $1,136,114 to $4,321,209 compared to $3,185,095 for the six months ended June 30, 2021. The increase in total revenue is primarily a result of the increased teleradiology revenue and the revenue produced from the acquisition of the IFH centres.

COST OF SALES

Physician Fees

For the six months ended June 30, 2022, the Company's physician fees totaled $2,779,859 higher by $309,233 compared to physician fees of $2,470,626 for the six months ended June 30, 2021. The increase in reading fees in the current six-month period is a result of the increased operations due to increased demand for the Company's services.

Technician Fees

For the six months ended June 30, 2022, the Company's technician fees totaled $245,074. There is no comparable data for the same period last year as this was directly related to the IHF acquisition in February 2022.

Medical Imaging Software

PACS costs for the six months ended June 30, 2022, was $129,718 compared to $85,608 for the six-month period ended June 30, 2021. This increase was related to an increase in patient volume requiring diagnostic interpretation during the second quarter for 2022. Additionally, the increased costs are partially offset by amounts we are able to collect in administrative revenues.

Supplies

For the six months ended June 30, 2022, the Company's supplies costs totaled $13,314. There is no comparable data for the same period last year as this was directly related to the IHF acquisition in February 2022.

TOTAL COST OF SALES

Total cost of sales during the first half of 2022 including physician fees, technician fees, medical imaging software, and supplies expenses were $3,167,966 compared to $2,556,234. Higher cost of sales experienced during the first half of 2022 was primarily a result of costs associated with the IHF acquisition in addition to increased operations due to higher demand for the Company's services.

GROSS PROFIT

As a result of the above revenues net of cost of sales, the Company's gross margin increased by $524,382 to $1,153,243 for the six-month period ending June 30, 2022, versus gross margin of $628,861 for the same six-month period in 2021.

EXPENSES

Stock Based Compensation

For the six months ended June 30, 2022, the Company recorded stock-based compensation of $219,666 compared to $603,021 for the same period in 2021. The decrease of $383,355 is due to a fewer amount of options granted in 2022 as compared to the year prior.

Salaries and Wages

For the six months ended June 30, 2022, the Company recorded salaries and wages of $452,427 compared to $602,937 for the same three-month period ended June 30, 2021. The decrease in salaries recorded in the second half of fiscal 2022 was a result of the re-capture of an allowance for additional payroll taxes.

Advertising and Marketing

For the six months ended June 30, 2022, the Company recorded advertising and marketing expenses for $16,402. Marketing and advertising expenses for the same period in 2021 was $381,006. The significant decrease in advertising and marketing expenses occurred in the first half of the quarter were partly for contracts signed in 2020 for investor outreach and institutional outreach related to the Company's qualifying transaction and listing on the TSXV exchange that did not continue into 2022.

Professional Fees

For the six months ended June 30, 2022, the Company recorded professional fees of $699,644 up considerably by $475,622 compared to $224,022 for the six months ended June 30, 2021. The increase in professional fees for the six months ended June 30, 2022, was primarily attributed to increased consulting fees in the second quarter due to revisions in management compensation contracts.

General and Administrative

General and administrative costs totaled $133,522 up $71,485 for the six months ended June 30, 2022, compared to general and administrative costs of $62,037 for the same six-month period in 2021. The Company experienced an increase in general and administrative costs during the current period in fiscal 2022, because of additional expenses incurred by the IHF centres.

Insurance

Insurance expense for the six months ended June 30, 2022, increased by $3,338 to $46,956 when compared to $43,618 for the same period in 2021.

Depreciation and Amortization

For the six months ended June 30, 2022, depreciation and amortization costs increased significantly by $77,668 to $94,033 compared to $16,365 for the same period in 2021. This increase was due to additional amortization and depreciation on equipment and property related to the IHF centres.

Premises Rental

For the six months ended June 30, 2022, the Company's premises rental costs increased by $17,717 to $23,338 compared to $5,621 for the same period in 2021. This increase reflects the rent due on the IHF centres.

TOTAL OPERATING EXPENSES

Total expenses for the six months ended June 30, 2022, were $1,685,988, lower by $252,639 when compared to total expenses of $1,938,627 for the six months ended June 30, 2021. The primary factors relating to the decrease in total expenses during the second quarter of 2022 were due the decrease in salaries and wages by $150,510, the stock-based compensation expenses which decrease by $383,355, and advertising and marketing expense which decreased by $364,604.

OTHER INCOME

For the six months ended June 30, 2022, other income was $94,217, whereas in 2021 for the same period it was $20,000. The increase in other income for the first half of 2022 is related to recapture of allowance for payroll taxes.

OTHER EXPENSES

Finance Costs

For the six months ended June 30, 2022, the Company recorded finance costs of $60,081 which increased significantly by $53,834 versus finance costs of $6,247 for the six-month period ended June 30, 2021. The increase in finance costs during the first half of 2022 was primarily related to interest on the TD Loan.

Broker Commissions

For the six months ended June 30, 2022, the Company recorded broker commission costs of $20,201. There was no comparable amount for the same period in 2021 as this relates to broker commission costs from private placement financing.

Reconciliation Discrepancies

For the six months ended June 30, 2022, the Company reconciliation discrepancies of $2,289. There was no comparable amount for the same period in 2021. These costs were directly related to reconciliation discrepancies which the company faced as a direct result of migrating between two accounting systems.

Other Miscellaneous Expenses

For the six months ended June 30, 2022 the Company recorded $100 for miscellaneous expenses, compared to $(14,030) that was recorded for the same period in 2021. The miscellaneous expenses recorded in 2021 were related to an accounts payable write-off that were no longer due.

Foreign Exchange Loss

Foreign exchange loss of $19 was recorded in the second half of 2022 compared to $3,951 for the same period in 2021.

TOTAL EXPENSES

Total expenses for the six months ended June 30, 2022, were $1,773,104, lower by $161,691 compared to $1,934,795 for the six-month period ended June 30, 2021. The decrease in total expenses for the six-month period ended June 30, 2022, was primarily related to salaries and wages, stock-based compensation and advertising and marketing expenses.

NET LOSS AND COMPREHENSIVE LOSS

As a result of the above factors, the net loss and comprehensive loss for the six months ended June 30, 2022, was $525,645 compared to a net loss and comprehensive loss of $1,285,934 for the six months ended June 30, 2020, an increase of $760,289.

LOSS PER SHARE – BASIC AND DILUTED

The loss per share-basic and diluted for the six months ended June 30, 2022, was $0.01 versus the loss per share-basic and diluted of $0.03 for the comparable six-month period in 2021.

PROPOSED TRANSACTIONS

The Company does not have any proposed transactions.

CHANGES IN ACCOUNTING POLICIES

The Company adopted an equipment depreciation schedule for its newly acquired medical equipment and leasehold improvements which includes a straight-line method and a useful life of 10 years. There were no other accounting policy changes in the first half of the year and none are planned for the remainder of 2022.

FINANCIAL INSTRUMENTS AND OTHER INSTRUMENTS

On February 1, 2022, the Company's subsidiary CTS borrowed $3,200,000 from TD Canada Trust. The initial term of the loan is 5 years with an initial 2-year interest rate of 4.02%. The loan is amortized over 10 years. Payments of principal and interest on the loan are due monthly. There is an additional annual payment of principal on the balance of the loan based on 25% of EBITDA of the Company's CTS subsidiary.

Credit risk

Credit risk is the risk of loss associated with a counter-party's inability to fulfill its payment obligations. The Company's cash and accounts receivable are exposed to credit risk. Jump's cash is held with a major Canadian-based financial institution and as such management believes that the associated credit risk is remote.

Account receivables represents revenue earned from services rendered to hospitals. The Company has adopted a credit policy under which each new customer is analyzed individually for creditworthiness before the Company's standard payment terms and conditions are offered.

The Company's trade receivables are concentrated among customers in the healthcare industry, which may be affected by adverse government policy impacting that industry. As at June 30, 2022, three customers accounted for greater than 63% of the Company's trade receivable balance.

There have been no changes to this risk exposure from 2021.

The Company's maximum exposure to credit risk as of June 30, 2022 and December 31, 2021, was as follows:

	June 30, 2022	December 31, 2021
Cash and Cash Equivalents	$ 1,296,558	$ 756,260
Accounts Receivable	801,008	727,983
Loans Receivable	1,270,251	556,521
Prepaid Expenses and Deposits	183,327	427,971
Total	**3,551,144**	**$ 2,468,735**

SHARE CAPITAL AND RESERVES

Authorized Share Capital

As at the date of filing this report the Company had 84,043,229 common shares outstanding. There are no other approved classes of shares for the Company.

Stock Options

As at the date of filing this report the Company had 9,334,890 options issued and outstanding, of which 6,686,890 are vested and exercisable into shares of common stock. (see Interim Financial Statements Note 14)

Warrants

As at the date of filing this report the Company had 40,860,261 common share purchase warrants issued and outstanding. (see Interim Financial Statements Note 15)

Broker Options

As at the date of filing this report the Company had 696,040 broker options issued and outstanding, each convertible into a unit consisting of 1 common share and 1 common share purchase warrant. (see Interim Financial Statements Note 16)